Skip to main content
SpringerLink
Log in

PET and PET/CT Imaging in Multiple Myeloma, Solitary Plasmacytoma, MGUS, and Other Plasma Cell Dyscrasias

  • Chapter
Positron Emission Tomography

Summary

In MM and related plasma cell dyscrasias, FDG-PET or PET/CT imaging are useful and reliable techniques for assistance in the diagnosis by identifying optimal sites for biopsy, for staging and restaging the tumor, for detecting extramedullary disease, and for monitoring response to treatment. They are equally effective in secretory or nonsecretory disease, with the latter developing with an increasing frequency during the course of the disease, causing difficulty in monitoring disease response or progression.

FDG-PET or PET/CT imaging are also useful techniques for detecting occult infection in patients with hematologic malignancies, for finding the source of infection, and for documenting response to treatment of infection, even in the setting of severe immunosuppression. The information gained by FDG-PET or PET/CT related to infectious disease often contribute to changes in patient management.

The presence of a high number of focal lesions, especially with cytogenetic abnormalities or chromosome 13 deletions, and/or the presence of extramedullary tumor, identifies patients at high risk with poor long-term prognosis who will need aggressive monitoring and treatment.

Failure to achieve normalization of FDG-PET or PET/CT images after treatment identifies patients at high risk for early relapse.

Progression of disease on treatment is a poor prognostic sign identifying patients in need of immediate intervention.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barlogie B, Shaughnessy J, Epstein J, Sanderson R, Anaissie R, Walker R, Tricot G. Plasma cell myeloma. In: Williams Hematology, 7th ed. New York: McGraw-Hill, 2005:.

    Google Scholar 

  2. Shaughnessy J, Barlogie B. Interpreting the molecular biology and clinical behavior of MM in the context of global gene expression profiling. Immunol Rev 2003;194:140–163.

    Article  PubMed  CAS  Google Scholar 

  3. Angtuaco EJC, Fassas AB, Walker RC, et al. Multiple myeloma: clinical review and diagnostic imaging. Radiology 2004; 231:11–23.

    PubMed  Google Scholar 

  4. Durie, B, Kyle, R, Belch, A, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003;4:379–398.

    Article  PubMed  Google Scholar 

  5. Walker R, Jones-Jackson L, Miceli M, et al. FDG PET functional imaging in multiple myeloma: clinically important caveats, pitfalls, and pearls. In: ASH Meeting 2004, San Diego. Blood 2004;104:11 (abstract).

    Article  Google Scholar 

  6. Walker R, Jones-Jackson L, Rasmussen E, et al. Rapid response to treatment of multiple myeloma detected with FDG PET scanning in multiple myeloma: early results from total therapy III. In: ASH Meeting 2004, San Diego. Blood 2004;104:11 (abstract).

    Article  Google Scholar 

  7. Walker R, Jones-Jackson L, Rasmussen E, et al. Diagnostic imaging of multiple myeloma: FDG PET and MRI complementary for tracking short vs. long term tumor response. In: ASH Meeting 2004, San Diego. Blood 2004;104:11 (abstract).

    Article  Google Scholar 

  8. Walker R, Jones-Jackson L, Rasmussen E, et al. MRI-detectable focal lesions (FL) in multiple myeloma (MM) at relapse frequently involve novel sites not involved at diagnosis. In: ASH Meeting 2004, San Diego. Blood 2004;104:11 (abstract).

    Article  Google Scholar 

  9. Orchard K, Barrington S, Buscombe A. et al. Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in MM. Br J Haematol 2002;117:133–135.

    Article  PubMed  Google Scholar 

  10. Schirrmeister H, Bommer M, Buck AK, et al. Initial results in assessment of MM using 18F-FDG PET. Eur J Nucl Med 2002;29:361–366.

    Article  CAS  Google Scholar 

  11. Durie B, Waxman A, D’Agnolo A, et al. Whole-body 18F-FDG PET identifies high-risk myeloma. J Nucl Med 2002;43:1457–1463.

    PubMed  Google Scholar 

  12. Durie BG, Salmon SE. A clinical staging system for MM: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer (Phila) 1975;36:842–854.

    Article  PubMed  CAS  Google Scholar 

  13. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103:20–32.

    Article  PubMed  CAS  Google Scholar 

  14. Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 2004;32:290–292.

    Article  PubMed  CAS  Google Scholar 

  15. Miceli MH, Atoui R, Walker R, et al. Diagnosis of deep septic thrombophlebitis in cancer patients by fluorine-18 fluorodeoxyglucose positron emission tomography scanning: a preliminary report. J Clin Oncol 2004;22:1949–1956.

    Article  PubMed  Google Scholar 

  16. Miceli MH, Jones-Jackson LB, Walker RC, et al. Diagnosis of infection of implantable central venous catheters by fluorine-18 fluorodeoxyglucose positron emission tomography. Nucl Med Commun 2004;25:813–818.

    Article  PubMed  Google Scholar 

  17. Anaissie E, Miceli M, Stroud S, et al. 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET): an important tool in the management of infection in patients with hematological cancer. In: ASH Meeting 2004, San Diego. Blood 2004;104:11 (abstract).

    Article  Google Scholar 

  18. Walker RC. Personal communication, unpublished data. University of Arkansas for Medical Sciences, Little Rock, AR, 2005.

    Google Scholar 

  19. O’Brien SN, Blijlevens NM, Mahfouz TH, et al. Infections in patients with hematological cancer: recent developments. Hematology (Am Soc Hematol Educ Program) 2003;438–472.

    Google Scholar 

  20. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer (Phila) 2004;100:228–237.

    Article  PubMed  Google Scholar 

  21. Sugawara Y. Infection and inflammation. In: Wahl R, Buchanam J, editors. Principles and Practice of Positron Emission Tomography, 1st ed. Philadelphia Lippincott Williams & Wilkins, 2002:381–394.

    Google Scholar 

  22. Stumpe KD, Dazzi H, Schaffner A, et al. Infection imaging using whole-body FDG-PET. Eur J Nucl Med 2000;27:822–832.

    Article  PubMed  CAS  Google Scholar 

  23. Zhuang H, Alavi A. 18-Fluorodeoxyglucose positron emission to-mographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002;32:47–59.

    Article  PubMed  Google Scholar 

  24. Rennen H, Boerman O, Oyen W, et al. Imaging infection/inflammation in the New Millennium. Eur J Nucl Med 2001;28:241–252.

    Article  PubMed  CAS  Google Scholar 

  25. De Winter F, Vogelaers D, Gemmel F, et al. Promising role of 18-F-fluoro-D-deoxyglucose positron emission tomography in clinical infectious diseases. Eur J Clin Microbiol Infect Dis 2002;21:247–257.

    Article  PubMed  Google Scholar 

  26. Gibel LJ, Hartshorne MF, Tzamaloukas AH. Indium-111 oxime leukocyte scan in the diagnosis of peritoneal catheter tunnel infections. Perit Dial Int 1998;18:234–235.

    PubMed  CAS  Google Scholar 

  27. Mettler F, Guiberteau M. Inflammation and infection imaging. In: Mettler F, editor. Essentials of Nuclear Medicine Imaging, 4th ed. Philadelphia: Saunders, 1998:387–403.

    Google Scholar 

  28. Wahl R. Principles of cancer imaging with fluorodeoxyglucose. In: Wahl R, editor. Positron Emission Tomography, 1st ed. Philadelphia: Lippincott Williams & Wilkins, 2002:100–110.

    Google Scholar 

  29. Avva R, Vanhemert R, Barlogie B, et al. CT-guided biopsy of focal lesions in patients with multiple myeloma may reveal new and more aggressive cytogenetic abnormalities. Am J Neuroradiol 2001;22:781–785.

    PubMed  CAS  Google Scholar 

  30. Callander NS, Roodman GD. Myeloma bone disease. Semin Hematol 2001;38:276–285.

    Article  PubMed  CAS  Google Scholar 

  31. Kyle R, Child JA, Anderson K, et al. Criteria for the classification of monoclonal gammopathies, MM and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749–757.

    Article  Google Scholar 

  32. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:4253–4254.

    Article  PubMed  Google Scholar 

  33. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillar Surg 2003;61:1115–1118.

    Article  Google Scholar 

  34. van Rhee F, Alikhan M, Munshi N, et al. Anti-IL6 antibody (ab) based strategies improve the management of HIV negative Castleman’s disease. In: ASH Meeting 2004, San Diego. Blood 2004;104:11 (abstract).

    Article  Google Scholar 

  35. Volberding P, Baker K, Levine A. Human immunodeficiency virus hematology. Hematology 2003;294–313 (www.hematology.org).

    Google Scholar 

  36. Brown, J, Skarkin A. Clinical mimics of lymphoma. Oncologist 2004;9:406–416.

    Article  PubMed  Google Scholar 

  37. Ghobrial IM, Gertz MA, Fonseca R. Waldenström macroglobulinaemia. Lancet Oncol 2003;4:679–685.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    Ronald C. Walker MD & Laurie B. Jones-Jackson MD

  2. Cancer Research and Biostatistics, Seattle, WA, USA

    Erik Rasmussen MS

  3. Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    Marisa Miceli MD, Frits Van Rhee MD, PhD, Joshua Epstein DSc, Elias J. Anaissie MD & Bart Barlogie MD, PhD

  4. Section of Neuroradiology Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    Edgardo J. C. Angtuaco MD

  5. Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    Guido J. Tricot MD, PhD

Authors
  1. Ronald C. Walker MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laurie B. Jones-Jackson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erik Rasmussen MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marisa Miceli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Edgardo J. C. Angtuaco MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Frits Van Rhee MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Guido J. Tricot MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Joshua Epstein DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Elias J. Anaissie MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Bart Barlogie MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Northern California PET Imaging Center, Sacramento, CA, USA

    Peter E. Valk MB, BS, FRACP

  2. Positron Emission Tomography, Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA

    Dominique Delbeke MD, PhD (Professor and Director of Nuclear Medicine) (Professor and Director of Nuclear Medicine)

  3. Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia

    Dale L. Bailey PhD (Associate Professor of Medicine) (Associate Professor of Medicine)

  4. Cancer Imaging and Tracer Development Program, The University of Tennessee Medical Center, Knoxville, TN, USA

    David W. Townsend PhD (Director) (Director)

  5. Department of Radiological Sciences, Guy’s and St Thomas’ Clinical PET Centre, Guy’s and St Thomas’ Hospital Trust, London, UK

    Michael N. Maisey BSc, MD, FRCR, FRCP (Professor of Emeritus) (Professor of Emeritus)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag London Limited

About this chapter

Cite this chapter

Walker, R.C. et al. (2006). PET and PET/CT Imaging in Multiple Myeloma, Solitary Plasmacytoma, MGUS, and Other Plasma Cell Dyscrasias. In: Valk, P.E., Delbeke, D., Bailey, D.L., Townsend, D.W., Maisey, M.N. (eds) Positron Emission Tomography. Springer, London . https://doi.org/10.1007/1-84628-187-3_19

Download citation

  • DOI: https://doi.org/10.1007/1-84628-187-3_19

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-971-5

  • Online ISBN: 978-1-84628-187-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation